Faron Pharmaceuticals Ltd of Finland has reported top-line, 12 month survival data for its antibody drug bexmarilimab showing that a significant number of patients who benefited from the treatment were still alive at 12 months. The Phase 1/2 MATINS study is investigating the safety and efficacy of bexmarilimab monotherapy in 10 different metastatic or inoperable solid tumour cohorts.
